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Abstract
Background: Behavioural changes associated with idiopathic epilepsy (IE) have been identified in dogs, with fear
and anxiety-related problems seen in both drug-naïve dogs and dogs treated with anti-epileptic drugs (AEDs).
Treating anxiety-related behaviour in dogs with IE may be challenging, as seizures are a contraindication for many
conventional anxiolytic drugs. In addition, many dogs with IE are already treated with AEDs to reduce their seizure
frequency, which may have negative effects if used in polytherapy. Imepitoin is low-affinity partial agonist at the
benzodiazepine (BDZ) site of the GABAA receptor, and has been demonstrated to have both anticonvulsant and
anxiolytic effects in laboratory rodents. Imepitoin has been developed for the treatment of IE in dogs, with
demonstrated anticonvulsant effects and high tolerability and safety. To date, imepitoin’s potential to reduce
anxiety in dogs with IE has not been investigated. An online survey was conducted to investigate the effect of
imepitoin on fear and anxiety-related behaviours in dogs with IE. Eighty-five valid responses were received from
owners of dogs with IE currently treated with imepitoin. Anxiety-related behaviour was quantified before and
during imepitoin treatment using a validated questionnaire tool (C-BARQ).
Results: No differences were observed in the five fear/anxiety-related measures between the two time periods (before
vs. during treatment) for dog directed fear, stranger directed fear, non-social fear, pain sensitivity and separation related
behaviour. A median 45% reduction in seizure frequency/month was observed following imepitoin treatment;
however, imepitoin did not appear effective in reducing seizure frequency in a minority of cases. Polyphagia was the
most common chronic side effect, and more side effects were reported in polytherapy cases.
Conclusions: Imepitoin does not appear to improve anxiety-related behaviour in dogs with IE treated with this
medication for its anti-epileptic effects. Investigating the effects of imepitoin upon the behaviour of dogs with
recognised behavioural anxiety-related problems (e.g. specific fears and phobias, separation related behaviours), in both
healthy dogs and dogs with epilepsy is required to further explore any potential anxiolytic effects of this medication.
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Background
There is mounting evidence that epilepsy is not simply a
seizure disorder, with the prevalence of psychiatric disor-
ders in people with epilepsy higher than in either the
general population or patients with other chronic med-
ical diseases [1–4]. The most common co-morbid
psychiatric disorders of epilepsy in people are anxiety
and depression [2, 5–8]. Comorbidities may be a cause
of epilepsy, a consequence of epilepsy, or a separate con-
dition that is associated with epilepsy because there is a
common cause for the epilepsy and the comorbidity [9].
The impact of co-morbid psychiatric disorders upon
patient quality of life (QoL) may be severe, with inter-
ictal anxiety and depression found to have greater ad-
verse effects on QoL than those of seizure frequency,
severity and chronicity [10]. As such, treatment that
does not simply focus upon seizure control may be
beneficial to the QoL of patients with epilepsy [9].
Co-morbid anxiety has recently been recognised in
dogs with idiopathic epilepsy (IE) [11], with behavioural
changes including increases in fear and anxiety associ-
ated with the development of IE [11]. Increased fear and
anxiety were observed in drug-naïve dogs as well as
those treated with AEDs, indicating these behavioural
changes were not merely a treatment side effect [11].
For example, in a recent study of epilepsy in the Italian
Spinone, 55% of dogs developed behavioural abnormal-
ities (commonly associated with anxiety) at epilepsy
onset, before the initiation of AEDs [12]. Due to the
potentially severe impact of anxiety upon QoL, addressing
this behavioural change alongside managing seizures
is desirable.
There are few psychopharmacological agents licensed
for use in dogs, and treating anxiety-related behaviour in
dogs with IE may be additionally challenging, as epilepsy
or a history of seizures are a contraindication for many
anxiolytic drugs. This includes the tri-cyclic antidepres-
sant (TCA) clomipramine, buspirone, and the selective
serotonin reuptake inhibitors (SSRI) fluoxetine, imipra-
mine, paroxetine, sertraline, amitriptyline and fluvoxamine
[13]. As such, there is a need for anxiolytic drugs that:
(i) Reduce anxiety without reducing the seizure
threshold in dogs with IE;
(ii)Have the potential to be administered as a
polytherapy alongside existing AEDs; and
(iii)Have a favourable side effect profile to allow their
long-term administration, if required.
Imepitoin is low-affinity partial agonist at the benzodi-
azepine (BDZ) binding site of the GABAA receptor.
Partial activation of the GABA receptors by imepitoin
has been demonstrated to have pronounced anti-seizure
activity and anxiolytic activity in rodent models, with a
high tolerability [14]. The anxiolytic effects of imepitoin
have been demonstrated in the rat in three experimental
paradigms, the Vogel conflict test, the elevated plus
maze and the light-dark box [15]. Imepitoin has been
developed as an antiepileptic drug for canine idiopathic
epilepsy (IE), with multiple studies indicating that it is
well tolerated in dogs, with antiepileptic effects observed
in both newly diagnosed IE cases as monotherapy and in
drug-resistant dogs as add-on treatment to phenobar-
bital [16–20]. The anxiolytic effects of imepitoin have
yet to be demonstrated in detail in the dog; however,
anecdotal evidence from the first clinical studies of ime-
pitoin indicated that owners perceived that their dog’s
epilepsy-related behavioural changes had improved
during imepitoin treatment, an effect not previously seen
with other anti-epileptic drugs (AEDs) such as pheno-
barbital [21]. Imepitoin has potential benefits over exist-
ing anxiolytics with a fast onset of action ~2–3 h post
oral dosing [14, 22], compared to around 3–5 weeks for
SSRIs and TCAs [23]. To date, the only behavioural
effect of imepitoin that has been reported is hyperactiv-
ity [18], which may be expected as paradoxical excite-
ment can occur in dogs treated with benzodiazepines
(e.g. diazepam) [24].
Whether imepitoin, a BDZ partial agonist, can be both an
effective anticonvulsant and anxiolytic in dogs with IE
requires further investigation. The purpose of this study
was to investigate the effect of imepitoin upon owner-
reported indicators of fear and anxiety-related behaviour in
dogs treated with imepitoin for IE, to investigate imepitoin’s
impact when administered as a polytherapy alongside other
AEDs, and to quantify imepitoin’s side effect profile when
used as a mono- or polytherapy.
Methods
Recruitment
A web-based questionnaire study was conducted to
investigate behavioural effects of imepitoin in dogs
treated with this medication for IE. Owners of dogs
currently being treated with imepitoin for IE were
recruited online via online (canine epilepsy forums, Twit-
ter, Facebook pages, the Royal Veterinary College and
Animal Health Trust websites) and via posters and leaflets
at local veterinary practices and breed association groups.
To be included in the study, dogs must have:
(1)Been diagnosed with IE either:
i. By a first opinion vet due to recurrent seizures for
more than 1 year, with the first seizure having
occurred while aged between 6 months to 6 years,
with no identifiable cause found (Tier I confidence
level for the diagnosis of IE [25]); OR
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ii. By a specialist in veterinary neurology with the aid
of blood tests (minimum data base blood tests [25])
and MRI of the brain
(2)Been treated with imepitoin for IE for a minimum of
4 weeks (28 days).
All dogs currently being treated with imepitoin were
eligible for this study, regardless of AED history to
include a breadth of cases. No pre-screening of anxiety
levels was conducted prior to inclusion in the study, to
allow the investigation of imepitoin’s effects upon dogs
with a wide spectrum of anxiety levels. Consent was
gained via a statement at the start of the questionnaire,
after the purpose of the study and potential use of the
results had been explained to the owner.
Questionnaire content
The survey was entitled “A questionnaire study of the
impact of Pexion (Imepitoin) on canine behaviour and
welfare” as not to bias responses towards owners of dogs
with anxiety problems, or dogs who had experienced
marked changes in anxiety following imepitoin treat-
ment. The survey was structured into four sections: clin-
ical history, behavioural changes, treatment efficacy and
side effects profile.
Clinical history
Owners reported their dog’s signalment, pedigree, age at
first seizure, seizure history, diagnostic tests performed
to diagnose IE, seizure frequency, experience of cluster
seizures, and frequency of cluster seizures and status
epilepticus (as defined by [26]), seizure semiology and
seizure recovery characteristics. AED treatment history
including the use of other anti-epileptic drugs was
recorded, and whether the dog was currently being
treated with imepitoin as a monotherapy or polytherapy.
Owners were asked to report their dog’s current dose of
imepitoin (mg) and their dog’s weight (kg).
Behavioural changes
Behavioural traits were quantified using a validated
questionnaire tool, the Canine Behavioral Assessment
and Research Questionnaire (C-BARQ) [27]. Owners
were questioned on their dog’s anxiety-related behaviour
before and during imepitoin treatment using five of the
eleven C-BARQ behavioural measures: ‘Dog directed
fear’, ‘Stranger directed fear’; ‘Non-social fear’; ‘Pain sen-
sitivity’ and ‘Separation related behaviour’. The C-BARQ
has previously been used to quantify neurobehavioral
changes in dogs with neurological disease, including IE
and syringomyelia [11, 28] and to quantify the impact of
a ketogenic dietary therapy upon the behaviour of dogs
with IE in a placebo-controlled crossover trial [29].
Treatment efficacy
The effect of imepitoin on seizure activity was recorded
via owner reports of the following measures both before
and during imepitoin treatment:
(i) Mean number of seizures/month;
(ii)Mean number of seizure days/month;
(iii)Mean number of cluster seizures/month (how many
times their dog experienced more than one seizure
in a 24 h period per month).
Owners were asked to estimate these measures from
the 3 months prior to imepitoin use, and for the entire
length of time they had been treated with imepitoin for.
The percentage change in the number of seizures/month
was calculated from measure (i) compared before and
during imepitoin treatment.
Side effects profile
Owners were questioned on the presence and severity of
11 AED side effects in the first 2 weeks of imepitoin
treatment, and after 2 weeks of imepitoin treatment:
polyphagia, polydipsia, polyuria, weight gain, increased
sleeping, ataxia, restlessness, pruritus, vomiting, diar-
rhoea and coughing. Owners were asked to report the
severity of these side effects on a five point scale of very
mild (1), mild (2), moderate (3), severe (4), and very
severe (5). Composite side effect scores were compiled
for the initial 2 weeks of treatment and after 2 weeks of
treatment by adding the scores of each of the 11 signs
(out of 55).
Statistical analysis
The five C-BARQ measures were calculated for each
dog using weighted scores, calculated using the loading
factors for each question established in the original
C-BARQ validation study multiplied by the owner’s
response to each question. Descriptive statistics were
calculated for each behavioural measure. Effects of treat-
ment protocol (dogs receiving mono or polytherapy with
imepitoin), cluster seizures, signalment and seizure fre-
quency before treatment were investigated for each
behavioural trait, measures of drug response and side
effect profiles. Data were visually examined for normality
of distribution using histograms. The Wilcoxon test was
used to compare continuous paired data e.g. C-BARQ
measures before and during imepitoin use, the Mann-
Whitey (U) tests for comparing continuous independent
data between two groups, and the Kruskall-Wallis (KW)
test for comparing continuous independent data be-
tween more than two groups. Chi-squared (X2) analysis
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was used to investigate associations between categorical
variables. All tests were two-sided and P < 0.05 was
considered to be significant. Data are presented as
mean (±SD), or median (25th–75th quartile), where
appropriate.
Results
Responses
Responses were received from 176 owners of which 85
were valid responses. Responses were deemed invalid
(n = 91) for the following reasons: n = 74 were incomplete
and could not be analysed, n = 9 dogs were deceased at
the time of response, n = 4 dogs were not receiving imepi-
toin at the time of response, n = 2 dogs were over the limit
of age at first seizure (without further veterinary diagnos-
tics to increase the confidence of an IE diagnosis), and
n = 2 had been diagnosed with structural epilepsy (caused
by identified cerebral pathology) [26].
Demographics – Owner
The majority of the owners responding were female
(77%, n = 65), with the most common age group being
46–60 years old (47.6%, n = 40), followed by 31–45
(32.1%, n = 27). The majority of responses were from
the UK (92.9%, n = 78), with 3.6% from Germany
(n = 3), 1.2% (n = 1) from Belgium, Spain, Sweden and
n = 1 owner did not disclose their location. The majority
of owners had heard about the survey via social media
(60.7%, n = 51), followed by web searches (21.4%,
n = 18), their regular vet (7.1%, n = 6) and their special-
ist vet (6.0%, n = 5). Nearly one third of dogs had
experienced a seizure within a week of their owner com-
pleting the survey (31.8%, n = 27), and a further 28.2%
1–3 weeks prior to completion.
Demographics - dog
Nearly two thirds of dogs were male (male neutered: 55.3%,
n = 47, male entire: 10.6%, n = 9), with around one third fe-
male (female neutered: 30.6%, n = 26, female entire 3.5%,
n = 3). The mean age (months) ± SD was 57.7 ± 29.6 months
and mean weight (kg) ± SD was 23.1 ± 12.3. The majority
of dogs were pure bred (78.8%, n = 67), with 34 different
breeds represented, and 21.2% were cross-bred (n = 18).
Almost half of all dogs were Kennel Club registered (48.2%,
n = 41). The most common breeds represented were the
Labrador Retriever (12.9%, n = 11), Border Collie (10.6%,
n = 9), Beagle (3.5%, n = 3), Golden Retriever (3.5%, n = 3)
and Italian Spinone (3.5%, n = 3).
Epilepsy phenotype
The median age (months) at first seizure (25th–75th
percentile) was 28.5 (18–46.3) months. The median total
number of seizures a dog had experienced was 12 (8–30).
Over half of dogs (55.3%, n = 47) had experienced cluster
seizures (more than one fit within 24 h), with 43.5% only
experiencing single seizures (n = 37) and 1.2% (n = 1) of
owners unsure.
Anti-epileptic drug treatment
The median time in days from first seizure to imepitoin
treatment was 275.0 (105.0–743.0). Imepitoin was
started after 2–5 seizures in the majority of dogs (41.2%,
n = 35), and after the first seizure in only 9.4% (n = 11)
of dogs. The median duration of imepitoin treatment
was 263.9 days (106.3–478.4). The mean dose of imepi-
toin was 23.37 mg/kg (SD: 6.43). The lowest dose was
10.0 mg/kg and the highest was 35.7 mg/kg, with the
majority of dogs receiving a dose between 20 and
30 mg/kg (53.5%).
Imepitoin was the first anti-epileptic medication re-
ceived for 65.9% of dogs (n = 56), with the other third of
dogs (32.9%, n = 28) having already received other anti-
epileptic drugs (AEDs). The majority of these dogs had
already been treated with phenobarbital (PB) (n = 22),
followed by potassium bromide (KBr) (n = 8), and leveti-
racetam (LEV) (n = 3). At the time of the survey, two
thirds of dogs were being treated with imepitoin as a
monotherapy (65.9%, n = 56) and one third were being
treated as a polytherapy (34.1%, n = 29) (Fig. 1). Of those
dogs receiving polytherapy, n = 21 were being treated
with PB, n = 13 with KBr and n = 8 with LEV. Nearly
one quarter of owners used rectal diazepam as an
emergency treatment (23.5%, n = 20).
Of the monotherapy cases (n = 56), imepitoin was the
first AED they were treated with for 76.8% of cases
(n = 43), with the remaining 21.4% (n = 13) having
previously been treated with other AED (s) whose use had
since been discontinued. Of the polytherapy cases
(n = 29), 44.8% (n = 13) had received imepitoin as their
dogs first AED with additional AEDs added at a later date,
and 55.2% (n = 16) received imepitoin as an add-on to
existing AED medication. There was a significant associ-
ation between cluster seizures and therapy type, with dogs
that only experienced single seizures more likely to be
treated with imepitoin as a monotherapy (83.6%) than as a
polytherapy (16.2%) (X2 = 9.81, p = 0.002).
Behavioural effects
No significant effect of imepitoin treatment was found
on the five behavioural measures, in either the whole
population (Table 1) or when only monotherapy cases
were considered (p > 0.05) (Fig. 2).
When only those monotherapy cases that were drug-
naive (had received no AED treatment prior to imepitoin
treatment, n = 43) were analysed, there was still no dif-
ference observed in any of the five behavioural measures
before and during treatment (p > 0.05). As dogs were
not selected based on high anxiety levels, to investigate
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the effect of imepitoin on only those dogs with higher
levels of anxiety within this population, analyses were
repeated including only those dogs with CBARQ scores
above the population median for each factor (Dog
directed fear: 0.543, Stranger directed fear: 0.203, Non-
social fear: 0.351, Pain sensitivity: 0.680, Separation
related behaviour: 0.088). Again, no effect of imepitoin
treatment upon the five measures was found in this
sub-population (p > 0.05).
There was no effect of signalment (sex, neuter status
or breed) on any of the five behavioural measures before
or during imepitoin treatment (p > 0.05). There was no
correlation between changes in any of the five behav-
ioural measures before or during imepitoin treatment
and drug response (as quantified by percentage change
(%) in seizure frequency; p > 0.05), or with the side
effects scores observed in either the first 2 weeks, or
after 2 weeks of treatment (p > 0.05).
Impact on seizure frequency
Significant reductions in seizures/month and clusters/
month were reported by owners while their dog was
treated with imepitoin compared to before imepitoin
treatment; however no significant change was seen in
the number of seizure days/month (Table 2). The
median reduction in seizure frequency following imepi-
toin treatment (number of seizures/month) was −1 (−2
to 0), and the median percentage change in seizure
frequency was a 45% reduction (−89.6% - 0%) across all
cases.
There was no significant difference in % reduction in
seizure frequency between dogs with or without cluster
seizures (Clusters median: 0% (−73.2% – 0%) vs. single
seizures median: −58.3% (−100% - 0%); Mann-Whitney
U = 863, p = 0.073). There was no significant difference
in % reduction in seizure frequency between dogs being
treated with imepitoin as a monotherapy or polytherapy
(Monotherapy median: −50% (−100% - 0%) vs. polyther-
apy median: 0% (−76.3%- +100%); Mann-Whitney
U = 820.5, p = 0.058). There was no association between
the number of seizures before initiation of imepitoin
treatment and the percentage change (%) in seizure
frequency (KW = 3.11, p = 0.375), or any effect of sex,
neuter status or breed on percentage change (%) in
seizure frequency (p > 0.05).
Side effects profile
The most common and severe side effect reported in both
the first 2 weeks and after 2 weeks of imepitoin treatment
was polyphagia. There was a significant reduction in the
Table 1 Five C-BARQ behavioural measures before and after imepitoin treatment in dogs treated with imepitoin with or without
other anti-epileptic drugs
Behavioural measure Before imepitoin treatment During imepitoin treatment Wilcoxon (W) N p
Dog directed fear 0.40 (0–1.09) 0.54 (0–1.09) 265.5 83 0.660
Stranger directed fear 0.19 (0–0.81) 0.19 (0–0.99) 206.0 84 0.946
Non-social fear 0.36 (0.09–0.78) 0.38 (0.11–0.85) 505.0 84 0.108
Pain sensitivity 0.62 (0–1.29) 0.62 (0.24–1.33) 307.0 83 0.125
Separation related behaviour 0.0 (0–0.33) 0.09 (0–0.47) 268 80 0.058
Data are presented as the median accompanied by 25th–75th percentiles
Fig. 1 Different uses of imepitoin as a monotherapy or a polytherapy in a study population of 85 dogs treated with imepitoin for idiopathic epilepsy
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side effect score before and after 2 weeks of treatment,
with the median side effect score in the first 2 weeks 13
out of 55 (4–19.5) and after the initial 2 weeks 9 out of 55
(1.5–15.5) (W = 247.5, p < 0.001) (Table 3).
The side effect score was greater in polytherapy cases
than in monotherapy cases in both the initial 2 weeks
(median monotherapy 10 (2–16) vs. median polytherapy
18 (8–24.5); Mann-Whitney U = 1098.5, p = 0.008) and
after the initial 2 weeks (median monotherapy 7 (1–
13.75) vs. median polytherapy 12 (7–18); Mann-Whitney
U = 1044.5, p = 0.030). In the first 2 weeks, differences
in side effect frequencies between monotherapy and
polytherapy cases were observed for: increased urinating
(X2 = 18.1, p = 0.03) and ataxia (X2 = 12.7, p = 0.026)
which were more common in polytherapy cases. After
2 weeks, differences in side effect frequencies between
monotherapy and polytherapy cases were observed for:
increased appetite (X2 = 11.5, p = 0.04), increased urinat-
ing (X2 = 11.4, p = 0.04), increased sleeping (X2 = 11.6,
p = 0.04) and ataxia (X2 = 14.7, p = 0.01) which were all
more common in polytherapy cases.
There was no correlation between treatment efficacy
(percentage change (%) in seizure frequency) or the
seizure frequency before imepitoin treatment was initi-
ated and the side effect score in either period (p < 0.05).
There was no relationship between side effect score and
any aspect of signalment (p > 0.05).
Discussion
This study for the first time investigated the impact of
an anti-epileptic drug used to treat seizures on fear and
anxiety-related behaviour in dogs with IE. The results
indicated that none of the five fear and anxiety-related
behavioural measures changed significantly following
treatment with imepitoin. It is possible that despite
being a partial GABAA agonist, imepitoin does not have
the same anxiolytic effects as other BDZ receptor
agonists or partial agonists, or that this effect does not
occur in dogs with IE. In line with previous reports,
anti-epileptic effects were seen in the majority of dogs,
with a median reduction in seizure frequency of
45%. Imepitoin side effects were generally mild and
Fig. 2 Box and whisker plot of the five C-BARQ behavioural measures before and after imepitoin treatment in dogs in dogs treated with only
imepitoin as a monotherapy (n = 56). The top and bottom lines of the boxes represent the 25th and 75th percentiles, the central line indicates
the median, and the whiskers represent the range. Filled circles represent outliers and stars represent extreme outliers
Table 2 Changes in seizure frequency following imepitoin treatment in both monotherapy and polytherapy cases
Seizure frequency measure Before imepitoin treatment During imepitoin treatment Wilcoxon (W) N P
Seizures/month 3.11 ± 4.02 1.93 ± 2.86 1256.0 76 0.002
Seizure days/month 2.31 ± 3.47 1.92 ± 3.30 802.5 74 0.105
Cluster seizure episodes/ month 0.91 ± 1.23 0.65 ± 1.34 461.0 77 0.038
Data are presented as the median accompanied by 25th–75th percentiles
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short-lived, with a significant reduction in the number
and severity of side effects observed after the initial
2 weeks of treatment. Ataxia, a common AED side effect
[30] was mild or not present in the majority of cases, in
line with recent objective evidence demonstrating
reduced levels in IE patients treated with imepitoin
compared to phenobarbitone [31]. A greater number of
side effects were seen in dogs treated with imepitoin
alongside other AEDs, which is in line with recent studies;
for example, when imepitoin was used as an add-on ther-
apy to phenobarbital, or vice versa, the number of side ef-
fects increased [32]. In addition, a recent study of
imepitoin polytherapy found that 69% of dogs treated with
imepitoin and KBr, and 79% of dogs treated with imepi-
toin and phenobarbital experienced side effects [33].
The lack of behavioural effects seen in this study may
be due to the IE study population not exhibiting a severe
enough initial anxiety level to allow for a significant
effect to be seen. Investigating the effects of imepitoin
upon the behaviour of dogs with recognised behavioural
anxiety-related problems (e.g. specific fears and phobias,
separation-related behaviours) +/− behavioural manage-
ment steps (e.g. desensitisation and counter-conditioning
[34]) is required to further explore any potential anxiolytic
effects of this medication in general. This may extend
beyond dogs, with imepitoin recently tested in clinic-
ally healthy cats in a randomised, controlled, blinded
study, and found to be well tolerated [35]. In a case
study of a 15 year old Persian cat with night-time vo-
calisation, 8 months of imepitoin treatment was found
to control the screaming which may indicate anxio-
lytic effects [36]. Further placebo-controlled studies
on a larger scale are required to confirm this effect in
both species.
Studying the anxiolytic effects of imepitoin in healthy
dogs and cats without epilepsy may provide further in-
sights into imepitoin’s efficacy as a behavioural medicine,
due to the potential differences between the healthy and
epileptic brain. It is possible that imepitoin may be an
effective anxiolytic in the ‘normal’ brain, but ineffective
in the epileptic brain (particularly in drug-resistant
patients). The majority of studies of the anxiolytic effects
of imepitoin have used either healthy animals or induced
models of epilepsy. Imepitoin has shown mixed results
in tests of anxiety in experimental animals (rats and
mice) [15, 37–45]. In rats, although anxiolytic activity
was shown in the elevated plus maze, Vogel conflict test,
light-dark chamber tests and social interaction test, these
effects were not seen in the Geller conflict test, a model
in which prior food-deprived rats have to choose be-
tween consuming food and avoiding the punishment
associated with this consumption. In mice, anxiolytic
activity was shown in the elevated plus maze and light-
dark chamber tests, but not in the four-plate test, where
mice are punished upon crossing the border between
four plates.
It is possible that behavioural changes such as anxiety
may be a sign of the natural progression of IE that
becomes worse over time. Imepitoin may have reduced
the progression of these changes in the current study
(hence the lack of change in the measured behavioural
traits); however, without a control group of dogs with IE
that were not treated with imepitoin or other AEDs over
a comparable period, this could not be detected in the
Table 3 Side effect score (out of 5) in the first 2 weeks and after 2 weeks of treatment with imepitoin in dogs treated with
imepitoin with or without other anti-epileptic drugs
Side effect All cases (n = 85)
(Median (25th–75th percentile)
Just imepitoin monotherapy cases (n = 56)
(Median (25th–75th percentile)
Initial 2 weeks After 2 weeks Initial 2 weeks After 2 weeks
Eating more / would like to eat more 3 (0–4) 2 (0–4) 2 (0–4) 1 (0–4)
Gaining weight 0 (0–3) 0 (0–2) 0 (0–3) 0 (0–2)
Drinking more 2 (0–3) 1 (0–3) 1 (0–3) 1 (0–2.75)
Urinating more 1 (0–3) 0 (0–2.5) 0 (0–3) 0 (0–2)
Sleeping more than before 1 (0–3) 0 (0–2) 1 (0–3) 0 (0–2.75)
Wobbly / not coordinated when walking 0 (0–3) 0 (0–1) 0 (0–1.75) 0 (0–0)
Restlessness / pacing 0 (0–3) 0 (0–2) 0 (0–2) 0 (0–1)
Itchiness or skin rash 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Vomiting 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Diarrhoea 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Coughing 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
OVERALL SCORE (out of 55) 13 (4–19.5) 9 (1.5–15.5) 10 (2–16) 7 (1–13.75)
Side effects were rated by owners on a six point scale from side effect not present (0), very mild (1), mild (2), moderate (3), severe (4), and very severe (5)
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current study. Understanding the progression of epilepsy
and its behavioural comorbidities is of high priority in
interpreting the effects of treatment interventions for
both seizure activity and behaviour.
Dog owners were used as the raters of canine behav-
iour in this study, as online questionnaires allow for
rapid acquisition of data on a sufficient number of ani-
mals for statistical purposes. Despite this positive aspect
of the study methodology, it is possible that owners may
not always be reliable raters of canine behaviour [46].
Questions in several of the studied C-BARQ measures
are prefixed with “Please assess the following situations
and determine how likely your dog is to respond in a
fearful or anxious way”, and it is possible that owners
were unable to correctly ascertain which behaviours
would indicate their dog was fearful or anxious in a situ-
ation. This may not have had a marked effect on the
current study, as fear is one of the most easily recog-
nised emotional states by owners in dogs [46, 47].
Including objective measures of fear and anxiety along-
side owner reports may clarify the results of future
studies. The success of existing anxiolytics is often
limited to owner reports of anxiety reduction after a
period of treatment. Herron et al. (2008) evaluated the
effects of diazepam in dogs with anxiety-related behav-
iour problems; however, their evaluation of efficacy was
based on owners rating the effectiveness of diazepam for
its prescribed indication as ‘very effective’, ‘moderately
effective’, ‘slightly effective’, or ‘not effective’ [24]. Al-
though a convenient way to question an owner’s percep-
tion of treatment success, results cannot be accurately
compared among owners, as perception of efficacy may
vary between individuals.
As these data were collected retrospectively, recall bias
may have reduced the reliability of the responses
received. Recall time varied between owners, with a
median of 263.9 days (106.3–478.4 days) since imepitoin
treatment commenced. Although this relatively long
time on this treatment allows sufficient time for effects
to be observed, it may be challenging for owners to ac-
curately recall their dog’s behaviour before imepitoin
treatment was initiated. To improve upon this limitation,
future studies should prospectively study the effects of
imepitoin and other AEDs on canine behaviour in a
longitudinal manner.
Despite the apparent lack of anxiolytic effects in this
study population, the anti-epileptic properties of imepi-
toin were apparent. A median 45% reduction in owner-
reported seizure frequency/month was observed follow-
ing imepitoin treatment. Significant reductions in seizure
frequency were observed following imepitoin treatment
for the measures ‘number of seizures/month’ and ‘num-
ber of clusters/month’; however, no difference was found
in number of seizure days/month. This may indicate that
the overall number of seizures that occurred was re-
duced within each day (i.e. clusters), but the number of
days they occurred upon did not change. The effective-
ness of imepitoin to treat dogs with cluster seizures has
not been studied to date, and thus imepitoin is not rec-
ommended as a primary treatment for dogs with cluster
seizures [48]. Over half of the dogs studied (55.3%,
n = 47) had experienced cluster seizures in this study
despite this recommendation, with no changes in
treatment efficacy found between clustering and non-
clustering dogs. As this study was not designed to assess
the efficacy of imepitoin as a treatment for cluster
seizures, further prospective studies are required to
investigate whether this is an appropriate treatment
option for this sub-population of dogs with epilepsy.
Seizure freedom remains the holy grail of epilepsy
treatment, and 14.1% of dogs became seizure free during
imepitoin treatment which is in line with some existing
estimates of AED-related remission [49]. However, the
remission rate observed in this study was significantly
lower than a previous investigation of imepitoin efficacy,
where complete suppression of generalized seizures was
observed in 46.9% of dogs (30/64) [19]. Remission rates
may differ significantly depending on study design,
duration of follow up and epilepsy phenotype of the
patients studied, and thus the dogs in this study may
have exhibited a more severe, drug-resistant form of IE.
The collection of retrospective seizure frequency data
from owners is a limitation of this study, as data may be
liable to recall bias and dependent upon the reliability of
the owner’s record keeping. The use of electronic seizure
diaries, which are becoming increasingly used by
owners, is likely to improve the reliability of owner
records, which are vital to epilepsy studies involving
client-owned animals. Encouraging owners to reliably
record seizures, using the same format of seizure diaries
may improve comparability of results across studies in
the future.
Polytherapy is commonly used in the management of
canine epilepsy, and when imepitoin monotherapy and
polytherapy cases were considered separately, 17.9% of
monotherapy cases became seizure free in comparison
to only 6.9% of polytherapy cases. This is unsurprising,
as it has previously been demonstrated that drug re-
sponse diminishes with the successive use of AEDs [50].
No predictors were found that were significantly associ-
ated with imepitoin drug-response and future research
should focus on this to elucidate why some dogs do not
experience a reduction in seizure frequency, or experi-
ence an increase in seizure frequency when receiving
imepitoin, while others become seizure free. Under-
standing whether using imepitoin in polytherapy with
other AEDs leads to significant improvements in seizure
frequency is of importance, as greater side effects were
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present in polytherapy patients in this study. Managing
the balance of seizure control vs. the impact of side ef-
fects remains a challenge in the optimisation of quality
of life in epilepsy patients [4, 51]. Exploring alternative
management options, including dietary therapy, may be
of benefit in the management of seizure activity and
anxiety in dogs experiencing adverse effects of polyther-
apy. Supplementation of alpha-casozepine and L-trypto-
phan [52] and a diet containing Valeriana officinalis,
Melissa officinalis and tryptophan [53] have been re-
ported to reduce anxiety-related behaviour in dogs; how-
ever, neither has been studied in dogs with epilepsy. In a
recent randomised, placebo-controlled, double-blinded
crossover trial of a ketogenic diet containing 10%
medium chain triglycerides, a reduction in stranger-
directed fear was observed alongside reduced seizure
frequency in dogs with idiopathic epilepsy, which may
indicate anxiolytic effects [54].
Conclusions
The data from this study are unable to provide evidence
of the anxiolytic effects of imepitoin when primarily used
to treat idiopathic epilepsy in dogs; however, anti-epileptic
effects were seen in the majority of dogs with generally
mild and short-lived side effects. It is possible that anxiety
levels in the IE population studied were not sufficiently
high to demonstrate an anxiety-reducing effect of imepi-
toin, and thus targeting dogs with or without epilepsy with
recognised behavioural problems may allow anxiolytic ef-
fects to be detected in future prospective studies.
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